Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian Porter

Showing results (21-30 of 50) with videos related to

Pageof 5
Sort By:
Clinical and Experimental Rheumatology|August 28, 2018
Secukinumab provides rapid and persistent relief in pain and fatigue symptoms in patients with ankylosing spondylitis irrespective of baseline C-reactive protein levels or prior tumour necrosis factor inhibitor therapy: 2-year data from the MEASURE 2 studyAtul Deodhar, Philip G Conaghan, Tore K Kvien, et al.
Arthritis Research & Therapy|December 24, 2017
Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3Karel Pavelka, Alan Kivitz, Eva Dokoupilova, et al.
Clinical and Experimental Rheumatology|May 19, 2017
Long-term effects of interleukin-17A inhibition with secukinumab in active ankylosing spondylitis: 3-year efficacy and safety results from an extension of the Phase 3 MEASURE 1 trialXenofon Baraliakos, Alan J Kivitz, Atul A Deodhar, et al.
The American Journal of Cardiology|July 24, 2012
Predicting risk of hospitalization or death among patients with heart failure in the veterans health administrationLi Wang, Brian Porter, Charles Maynard, et al.
Journal of General Internal Medicine|June 23, 2019
Automated Self-management (ASM) vs. ASM-Enhanced Collaborative Care for Chronic Pain and Mood Symptoms: the CAMMPS Randomized Clinical TrialKurt Kroenke, Fitsum Baye, Spencer G Lourens, et al.
Journal of Medical Radiation Sciences|September 4, 2020
Rolling out RapidPlan: What we've learntKirsten van Gysen, James O'Toole, Andrew Le, et al.
The Journal of Rheumatology|June 17, 2019
Secukinumab Immunogenicity over 52 Weeks in Patients with Psoriatic Arthritis and Ankylosing SpondylitisAtul Deodhar, Dafna D Gladman, Iain B McInnes, et al.
Annals of the Rheumatic Diseases|September 2, 2016
Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 StudyJoachim Sieper, Atul Deodhar, Helena Marzo-Ortega, et al.
Clinical Drug Investigation|January 27, 2020
Comparison of the Effects of Secukinumab and Adalimumab Biosimilar on Radiographic Progression in Patients with Ankylosing Spondylitis: Design of a Randomized, Phase IIIb Study (SURPASS)Xenofon Baraliakos, Mikkel Østergaard, Lianne S Gensler, et al.
Contemporary Clinical Trials|October 17, 2017
Comprehensive vs. Assisted Management of Mood and Pain Symptoms (CAMMPS) trial: Study design and sample characteristicsKurt Kroenke, Erica Evans, Sharon Weitlauf, et al.
Pageof 5

Showing results (21-30 of 50) with videos related to

Sort By:
Pageof 5
Clinical and Experimental Rheumatology|August 28, 2018
Secukinumab provides rapid and persistent relief in pain and fatigue symptoms in patients with ankylosing spondylitis irrespective of baseline C-reactive protein levels or prior tumour necrosis factor inhibitor therapy: 2-year data from the MEASURE 2 studyAtul Deodhar, Philip G Conaghan, Tore K Kvien, et al.
Arthritis Research & Therapy|December 24, 2017
Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3Karel Pavelka, Alan Kivitz, Eva Dokoupilova, et al.
Clinical and Experimental Rheumatology|May 19, 2017
Long-term effects of interleukin-17A inhibition with secukinumab in active ankylosing spondylitis: 3-year efficacy and safety results from an extension of the Phase 3 MEASURE 1 trialXenofon Baraliakos, Alan J Kivitz, Atul A Deodhar, et al.
The American Journal of Cardiology|July 24, 2012
Predicting risk of hospitalization or death among patients with heart failure in the veterans health administrationLi Wang, Brian Porter, Charles Maynard, et al.
Journal of General Internal Medicine|June 23, 2019
Automated Self-management (ASM) vs. ASM-Enhanced Collaborative Care for Chronic Pain and Mood Symptoms: the CAMMPS Randomized Clinical TrialKurt Kroenke, Fitsum Baye, Spencer G Lourens, et al.
Journal of Medical Radiation Sciences|September 4, 2020
Rolling out RapidPlan: What we've learntKirsten van Gysen, James O'Toole, Andrew Le, et al.
The Journal of Rheumatology|June 17, 2019
Secukinumab Immunogenicity over 52 Weeks in Patients with Psoriatic Arthritis and Ankylosing SpondylitisAtul Deodhar, Dafna D Gladman, Iain B McInnes, et al.
Annals of the Rheumatic Diseases|September 2, 2016
Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 StudyJoachim Sieper, Atul Deodhar, Helena Marzo-Ortega, et al.
Clinical Drug Investigation|January 27, 2020
Comparison of the Effects of Secukinumab and Adalimumab Biosimilar on Radiographic Progression in Patients with Ankylosing Spondylitis: Design of a Randomized, Phase IIIb Study (SURPASS)Xenofon Baraliakos, Mikkel Østergaard, Lianne S Gensler, et al.
Contemporary Clinical Trials|October 17, 2017
Comprehensive vs. Assisted Management of Mood and Pain Symptoms (CAMMPS) trial: Study design and sample characteristicsKurt Kroenke, Erica Evans, Sharon Weitlauf, et al.
Pageof 5